Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$29.17 USD
-0.07 (-0.24%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $29.19 +0.02 (0.07%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IART 29.17 -0.07(-0.24%)
Will IART be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IART
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Investors Should Retain Integra (IART) Stock Now
Why Is Integra (IART) Down 4% Since Last Earnings Report?
Integra LifeSciences (IART) Introduces MicroMatrix Flex
Other News for IART
Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
Buy Rating for Integra Lifesciences Amid Favorable Medicare Policy Changes
Medicare Administrators looking to 'drastically shake up' wound care, says BTIG
Warning: IART is at high risk of performing badly
First Week of December 20th Options Trading For Integra LifeSciences Holdings (IART)